Poor treatment of asthma and COPD puts a huge burden on the NHS. For example, £1 billion is spent on asthma treatment in the UK each year and represents 60,000 to 65,000 hospital admissions. In ...
Flare-ups in chronic obstructive pulmonary disease, the UK’s fourth leading cause of death, can be reduced by 20% by a combined triple inhaler, according to the results of a trial of more than 2,000 ...
Available treatments for COPD are mainly palliative ... destruction of the airways associated with the disease 7. Inhaled corticosteroids (ICS), short- and long-acting β 2-agonists (SABA and ...
AstraZeneca may mount a challenge to GlaxoSmithKline’s three-in-one inhaler for chronic obstructive pulmonary disease (COPD) after a late-stage trial success. AZ’s single inhaler, PT010 ...
Purpose. Special considerations in the selection of medication inhaler devices for elderly patients with chronic obstructive pulmonary disease (COPD) in the ambulatory care setting are reviewed.
Scientists have found a new treatment for people with asthma and chronic obstructive pulmonary disease (COPD) that may be more effective than current options. Over the past 50 years, treatment options ...
A review of the literature was conducted to examine the clinical effectiveness of inhaled GSH as a treatment for various pulmonary diseases and respiratory-related conditions. This report also ...
Companies like AstraZeneca and GSK, which have high-revenue-generating inhalers for asthma and chronic obstructive pulmonary disorder (COPD) in their portfolios, have each committed to becoming ...
“In Bermuda, there are effective medications, primarily inhalers, designed to manage COPD symptoms. Patients typically take one or two doses daily, along with an additional dose of a different ...